ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SBIO ALPS Medical Breakthroughs ETF

31.83
0.30 (0.95%)
Last Updated: 09:57:42
Delayed by 15 minutes

Period:

Draw Mode:

Volume 548
Bid Price
Ask Price
News -
Day High 31.83

Low
23.21

52 Week Range

High
38.80

Day Low 31.62
Company Name Etf Ticker Symbol Market Type
ALPS Medical Breakthroughs ETF SBIO AMEX Exchange Traded Fund
  Price Change Change Percent Etf Price Last Traded
0.30 0.95% 31.83 09:57:42
Open Price Low Price High Price Close Price Prev Close
31.62 31.62 31.83 31.53
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
16 548  31.68  17,362 - 23.21 - 38.80
Last Trade Time Type Quantity Etf Price Currency
09:57:11 2  31.865 USD

ALPS Medical Breakthroughs ETF Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
100.11M 3.18M - 163k -17.09M -5.38 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News ALPS Medical Breakthroug...

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SBIO Message Board. Create One! See More Posts on SBIO Message Board See More Message Board Posts

SBIO Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week31.7332.7131.0031.7121,2800.100.32%
1 Month35.6635.6631.0032.8712,064-3.83-10.74%
3 Months33.5938.8031.0035.0613,733-1.76-5.24%
6 Months24.1738.8023.2132.2412,0657.6631.69%
1 Year29.8638.8023.2131.1410,3451.976.60%
3 Years48.7950.9823.2134.8417,146-16.96-34.76%
5 Years34.4464.0423.2138.4926,631-2.61-7.58%

The Fund seeks investment results that correspond before fees and expenses generally to the performance of its underlying index the Poliwogg Medical Breakthroughs ndexSM ticker symbol PMBI the Underlying Index. The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Your Recent History

Delayed Upgrade Clock